ストックスクリーナーアプリを入手
0.7812
2.52%
0.0192
アフターアワーズ：
.76
-0.0212
-2.71%
Cue Biopharma Inc (CUE) 最新ニュース
Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia
Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa
Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals
Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN
Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus
Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology
Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq
Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma
Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech
Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard
Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter
Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India
Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia
Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus
Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus
Cue Biopharma Prices $20 Million Public Offering of Stock, Warrants - marketscreener.com
Boehringer Ingelheim and Cue Biopharma partner to develop next-g - GuruFocus
Cue Biopharma Announces Proposed Public Offering | CUE Stock New - GuruFocus
Cue Biopharma (CUE) Stock Dips Amid $20M Public Offering Announcement - GuruFocus
Cue Biopharma Prices About $20 Mln Public Offering - Nasdaq
Cue Biopharma Announces Pricing of Approximately $20 Million Pub - GuruFocus
Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789 - MarketScreener
$20M Capital Raise: Inside Cue Biopharma's Latest Strategic Financing Move - Stock Titan
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - The Manila Times
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - Benzinga
Boehringer, Cue Biopharma ink autoimmune therapy deal By Investing.com - Investing.com South Africa
Cue Biopharma inks deal with Boehringer Ingelheim By Investing.com - Investing.com South Africa
Cue Biopharma launches public stock offering By Investing.com - Investing.com Canada
Cue Biopharma launches public stock offering - Investing.com Australia
Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments - MarketScreener
Cue Biopharma inks deal with Boehringer Ingelheim - Investing.com
Boehringer, Cue Biopharma ink autoimmune therapy deal - Investing.com
Form 424B5 Cue Biopharma, Inc. - StreetInsider
Cue Biopharma Announces Proposed Public Offering - The Manila Times
Cue Biopharma Seeks Fresh Capital: New Public Offering to Fund Cancer Therapeutics - Stock Titan
Cue Biopharma to Host Business Update Call and Webcast - Enidnews.com
Boehringer Ingelheim and Cue Biopharma partner to develop - GlobeNewswire
‘Buy These Two Chip Stocks Ahead of a Recession,’ Says Citi - The Globe and Mail
S&P 500 jumps 1.8% as Wall Street closes a chaotic and historic week - The Globe and Mail
Can Spotify’s (SPOT) Ad Business Hit the Right Notes in 2025? - The Globe and Mail
Seeking High Dividend Yield? Earn 9.6% from This Energy Stock Now. - The Globe and Mail
EXL Schedules First Quarter 2025 Financial Results Conference Call - The Globe and Mail
Will Tariffs Destroy This Clothing Giant? - The Globe and Mail
United Community Banks, Inc. Announces Date for First Quarter 2025 Earnings Release and Conference Call - The Globe and Mail
Vision Marine Technologies Strengthens Innovation with New Patent Filing for Secure Vessel Connectivity - The Globe and Mail
Form 8-KCurrent report - ADVFN
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):